Analytical Data
-
Gene name
CLDN18
- Application
-
Alternative Names
SFTP-J; SFTPJ; SP-J; SPJ; Surfactant Protein J; Surfactant Associated Protein J
-
Species
Human
-
Source
E. coli
-
Tag
N-His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P56856
-
Expression Region
Cys196~Val261
-
Molecular Weight
14kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
CLDN18 (Claudin-18) is a member of the claudin family of proteins, which play a crucial role in the formation of tight junctions between epithelial cells, thereby regulating paracellular permeability and maintaining cellular integrity. The research on CLDN18 has gained significant attention due to its implications in various diseases, particularly in cancer. Specifically, aberrant expression of CLDN18 has been associated with gastric and pancreatic cancers, making it a promising target for therapeutic intervention and diagnostic applications. The existence of specific isoforms of CLDN18, including CLDN18.2, has been identified, leading to the development of monoclonal antibodies targeting these isoforms. These antibodies have shown potential in the creation of novel immunotherapeutic strategies, including antibody-drug conjugates and CAR T-cell therapies. Furthermore, understanding the structural and functional aspects of CLDN18 through recombinant protein studies is essential for unraveling its role in tumor biology and for translating these insights into clinical practice. Overall, research on CLDN18 recombinant proteins holds significant promise for improving cancer diagnosis and treatment, thereby enhancing patient outcomes.
